Anti-Inflammatory and Antidiabetic Metabolites From Mitragyna diversifolia: In Vitro, Phytochemical, and
Jing Lu1,2, Hanlei Wang1,2, Kun Zhang1,2
1Xishuangbanna Tropical Botanical Garden, Chinese Academy of Sciences, Kunming, China.
Abstract:
Mitragyna diversifolia is commonly used to cure diarrhoea in the Bandarban region. However, the impact of anti-inflammatory properties and underlying material basis remains unexplored. This study aimed to determine the anti-inflammatory and antidiabetic potential of metabolites from M. diversifolia. The results indicated that 2,4-di-tert-bylphenol (8), cryptotanshinone (9), and dihydrotanshinone I (10) not only effectively inhibited LPS-induced NO production but also demonstrated potential antidiabetic activities by promoting glucose uptake. Network pharmacological analysis, molecular docking, and molecular dynamics simulation revealed that AKT1 was a crucial target for the anti-inflammatory and antidiabetic effects of M. diversifolia. At the same time, molecular docking analysis showed that compounds 8, 9, and 10 possessed superior binding capacities with AKT1 (-7.3, -11.9, and -11.7 kcal/mol, respectively). Collectively, this study preliminarily clarified the possible material basis and mechanism of M. diversifolia to prevent inflammation and diabetes. Further research is needed to determine the in vivo conditions of compounds 8, 9, and 10, particularly with regard to their safety and efficacy.
More Related Videos
07:36Analysis of Raw and Processed Cyperi Rhizoma Samples Using Liquid Chromatography-Tandem Mass Spectrometry in Rats with Primary Dysmenorrhea
Published on: December 23, 2022
11:06Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
Published on: April 7, 2023
Related Concept Videos
Oral Hypoglycemic Agents: Biguanides and Glitazones
Oral Hypoglycemic Agents: Glinides
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are typically...
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Dipeptidyl Peptidase 4 Inhibitors
